TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCTS LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 SECONDARY SOURCES
2.10 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 CLINICAL TRIALS
4.2 RECENT DEVELOPMENTS
4.3 BRAND COMPETITIVE ANALYSIS
4.4 SUPPLY CHAIN ANALYSIS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISING INCIDENCES OF INBORN ERRORS OF METABOLISM
5.1.2 PREFERENCE OF DIETARY SUPPLEMENTS OVER ENZYME REPLACEMENT THERAPY
5.1.3 GOVERNMENT INITIATIVES AND PROGRAMS FOR CREATING AWARENESS ABOUT IEM
5.1.4 INCREASE IN THE NUMBER OF NEW BORN SCREENING PROCEDURES
5.2 RESTRAINTS
5.2.1 INADEQUATE REIMBURSEMENT SCENARIO
5.2.2 STRINGENT REGULATIONS FOR MEDICAL FOODS
5.2.3 HIGH COST OF MEDICAL FOODS
?
5.3 OPPORTUNITIES
5.3.1 INNOVATIVE PRODUCT LAUNCHES FOR NEW INDICATIONS
5.3.2 INCREASING SPENDING ON MEDICAL FOODS PRODUCTS
5.4 CHALLENGES
5.4.1 PRODUCT RECALLS
5.4.2 POOR ACCESSIBILITY OF MEDICAL FOODS
6 COVID-19 IMPACT ANALYSIS
7 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS
7.1 OVERVIEW
7.2 AMINO ACID
7.2.1 SINGLE AMINO ACID
7.2.1.1 L-ARGININE
7.2.1.2 L-ISOLEUCINE
7.2.1.3 L-TYROSINE
7.2.1.4 L-LEUCINE
7.2.1.5 GLYCINE
7.2.1.6 OTHERS
7.2.2 AMINO ACID MIXTURES
7.2.2.1 PHENYLADE
7.2.2.1.1 DRINK MIX
7.2.2.1.2 GMP MIX-IN
7.2.2.1.3 GMP READY
7.2.2.1.4 OTHERS
7.2.2.2 PERIFLEX
7.2.2.3 LOPHLEX
7.2.2.4 PHLEXY
7.2.2.5 COOLER
7.2.2.6 ANAMIX
7.2.2.7 LYSINE-FREE, LOW TRYPTOPHAN
7.2.2.8 GLUTARADE ESSENTIAL GA-1
7.2.2.9 GLUTARADE GA-1 AMINO ACID BLEND
7.2.2.10 GLYTACTIN WITH GMP
7.2.2.11 OTHERS
7.3 LOW PROTEIN FOOD
7.4 GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON
7.5 LOW-CALCIUM/VITAMIN D-FREE INFANT FORMULA WITH IRON
7.6 OTHERS
8 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY AGE GROUP
8.1 OVERVIEW
8.2 INFANTS
8.3 WEANING
8.4 ADOLESCENT
8.5 ADULTS
9 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES
9.1 OVERVIEW
9.2 PHENYLKETONURIA (PKU)
9.2.1 PHENYLADE
9.2.2 PERIFLEX
9.2.3 LOPHLEX
9.2.4 OTHERS
9.3 TYROSINEMIA TYPES I AND II
9.4 MAPLE SYRUP URINE DISEASE (MSUD)
9.4.1 ANAMIX
9.4.2 COOLER
9.4.3 MSUD GEL
9.4.4 AMINO ACID BLEND
9.4.5 MAXMUM
9.4.6 OTHERS
9.5 HOMOCYSTINURIA
9.6 GLUTARIC ACIDEMIA TYPE I
9.7 UREA CYCLE DISORDERS
9.8 METHYLMALONIC ACIDEMIA
9.9 ISOVALERIC ACIDEMIA
9.10 ORGANIC ACIDURIAS
9.11 RENAL DISEASE
9.12 PROPIONIC ACIDEMIA
9.13 DISORDERS OF LEUCINE METABOLISM
9.14 OTHERS
10 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FORM
10.1 OVERVIEW
10.2 POWDER
10.3 LIQUID
10.4 OTHERS
11 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PACKAGING
11.1 OVERVIEW
11.2 CAN
11.3 PACKET
11.4 BOTTLE
11.5 JAR
11.6 OTHERS
12 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 RETAIL PHARMACIES
12.3 HOSPITAL PHARMACIES
12.4 DRUGS STORES
12.5 ONLINE PHARMACIES
12.6 OTHERS
13 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION
13.1 EUROPE
13.1.1 GERMANY
13.1.2 FRANCE
13.1.3 U.K.
13.1.4 ITALY
13.1.5 SPAIN
13.1.6 SWITZERLAND
13.1.7 NETHERLANDS
13.1.8 BELGIUM
13.1.9 DENMARK
13.1.10 RUSSIA
13.1.11 SWEDEN
13.1.12 TURKEY
13.1.13 POLAND
13.1.14 REST OF EUROPE
14 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: EUROPE
15 COMPANY PROFILE
15.1 ABBOTT
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENT
15.2 BIOMARIN
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 MEAD JOHNSON & COMPANY, LLC. (A SUBSIDIARY OF RECKITT BENCKISER GROUP PLC.)
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.4 NESTLe HEALTH SCIENCE (A SUBSIDIARY OF NESTLe)
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 AJINOMOTO CAMBROOKE, INC. (A SUBSIDIARY OF AJINOMOTO CO., INC.)
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENTS
15.6 APR
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
?
15.7 DR. SCHaR AG / SPA
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENT
15.8 ENER-G FOODS, INC.
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 NUTRICIA (A SUBSIDIARY OF DANONE)
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENT
15.10 PKU-MDMIL
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 POA PHARMA
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.12 PRISTINE ORGANICS PRIVATE LIMITED
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENT
15.13 PROMIN METABOLICS
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 SOLACE NUTRITION
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
?
16 SWOT & DATA BRIDGE MARKET RESEARCH ANALYSIS
16.1 SWOT ANALYSIS
16.1.1 STRENGTH: - STRONG PRODUCT PORTFOLIO
16.1.2 WEAKNESS: - NO INITIATIVES FOR EXPANSION
16.1.3 OPPORTUNITY: - INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT
16.1.4 THREAT: - STIFF COMPETITION
16.2 DATA BRIDGE MARKET RESEARCH ANALYSIS
17 CONCLUSION
18 QUESTIONNAIRE
19 RELATED REPORTS